...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
【24h】

Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series

机译：利拉鲁肽减少肥胖和2型糖尿病患者的内脏脂肪和肝内脂肪，而无明显的肌肉块减少：

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Glucagon-like peptide-1 receptor agonists have been reported to reduce body fat as well as improving glycemic control in obese patients with type 2 diabetes. However, the maximum dose of liraglutide is limited to 0.9 mg in Japan, while the international dose is 1.8 mg; and the effect of this low dose on body composition has not been assessed in detail. Accordingly, this study was performed to evaluate the effect of liraglutide on body composition when administered at 0.9 mg once daily for 24 weeks. Methods: Nine patients were enrolled and started liraglutide at 0.3 mg once daily, which was titrated to 0.9 mg once daily after 1 - 2 weeks and continued for 24 weeks. To comprehensively investigate changes of body composition, the body fat and muscle weight were determined by dual energy absorptiometry, visceral fat volume (VFV) and abdominal subcutaneous fat volume (SFV) were measured by abdominal computed tomography (CT), and the intrahepatic lipid content (IHL) was assessed by proton magnetic resonance spectroscopy. Measurements were obtained before starting liraglutide therapy and after 12 and 24 weeks of treatment. Results: Fasting plasma glucose was significantly reduced from 127 ± 22 to 101 ± 14 mg/dL at 24 weeks and hemoglobin A1c (HbA1c) showed significant reduction from 6.4±0.9% to 5.2±0.5%. Body weight was reduced from 103.4 ± 14.7 to 97.0 ± 12.4 kg (mean reduction: 11.7%) and BMI decreased from 37.4 ± 6.4 to 35.0 ± 5.3 kg/msup2/sup (mean reduction: 5.8%). Furthermore, VFV and IHL decreased from 5,192 ± 1,730 to 4,513 ± 1,299 cmsup3/sup (mean reduction: 11.9%) and 32.1±12.6% to 15.2±9.2% (mean reduction: 49.2%), respectively, but SFV did not change. Moreover, the fat index was reduced from 14.8 ± 4.4 to 12.9 ± 3.4 kg/msup2/sup (mean reduction: 10.9%), but the skeletal muscle index did not change. Conclusions: In obese Japanese drug-naive patients who had type 2 diabetes, treatment with liraglutide (0.9 mg once daily for 24 weeks) reduced body fat, especially visceral fat and intrahepatic fat, while having no significant effect on skeletal muscle.
机译：背景：据报道，胰高血糖素样肽1受体激动剂可减少肥胖的2型糖尿病患者的体内脂肪并改善血糖控制。但是，在日本，利拉鲁肽的最大剂量限制为0.9毫克，而国际剂量为1.8毫克;并且尚未详细评估这种低剂量对人体组成的影响。因此，进行这项研究是为了评估利拉鲁肽在以0.9 mg每天一次给药持续24周时对人体组成的影响。方法：9名患者入组并开始每日一次0.3 mg利拉鲁肽，然后在1-2周后每天一次滴定至0.9 mg，并持续24周。为了全面调查人体成分的变化，通过双能吸收法测定人体脂肪和肌肉重量，通过腹部CT（CT）测量内脏脂肪量（VFV）和腹部皮下脂肪量（SFV），以及肝内脂质含量（IHL）通过质子磁共振波谱进行评估。在开始利拉鲁肽治疗之前和治疗12和24周后获得测量值。结果：空腹血糖在24周时从127±22 mg / dL显着降低至101±14 mg / dL，血红蛋白A1c（HbA1c）从6.4±0.9％显着降低至5.2±0.5％。体重从103.4±14.7千克降低到97.0±12.4千克（平均降低：11.7％），体重指数从37.4±6.4千克降低到35.0±5.3 kg / m 2 （平均降低：5.8％）。此外，VFV和IHL分别从5,192±1,730降至4,513±1,299 cm 3 （均值降低：11.9％）和32.1±12.6％至15.2±9.2％（均值降低：49.2％），但是SFV并没有改变。此外，脂肪指数从14.8±4.4降至12.9±3.4kg / m 2 （平均降低：10.9％），但骨骼肌指数没有变化。结论：在肥胖的日本2型糖尿病初治患者中，利拉鲁肽（每天0.9 mg，连续24周）治疗可减少体内脂肪，特别是内脏脂肪和肝内脂肪，而对骨骼肌无明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号